Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Cencora Inc.

Ecora Royalties PLC ( ($GB:ECOR) ) has issued an announcement. Ecora Royalties PLC will hold a live interactive presentation on 14 April 2026 to di...

Ecora to Host Investor Presentation on 2025 Results via Engage Platform

A class action lawsuit was filed against Corcept Therapeutics ($CORT) on February 20, 2026. Plaintiffs -shareholders- in the federal securities cla...

Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims

Berenberg Bank analyst maintained a Buy rating on Ecora Royalties PLC yesterday and set a price target of p180.00. In addition to Berenberg Bank, E...

Berenberg Bank Reaffirms Their Buy Rating on Ecora Royalties PLC (ECOR)

Cora Gold ( ($GB:CORA) ) has provided an update. Cora Gold Limited, the AIM-quoted West African gold developer, has closed a previously announced f...

Cora Gold Closes £15.7m Fundraise and Expands Share Option Pool

There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Ottobock SE & Co. KGaA (OBCKF) and Corcept Therapeutics (COR...

Analysts Are Bullish on Top NA Stocks: Ottobock SE & Co. KGaA (OBCKF), Corcept Therapeutics (CORT)

In a report released on March 26, Ben Davis from RBC Capital maintained a Buy rating on Ecora Royalties PLC, with a price target of p190.00. The co...

RBC Capital Reaffirms Their Buy Rating on Ecora Royalties PLC (ECOR)

Cora Gold ( ($GB:CORA) ) has provided an update. Cora Gold has completed a £15.7m equity fundraise via a subscription and retail offering at 6 penc...

Cora Gold Raises £15.7m, Reshapes Board as Eagle Eye Takes 29.9% Stake

Corcept Therapeutics (CORT) told investors approval was on track through December 2025. Then the company disclosed that the FDA had issued a Comple...

Corcept Faces Investor Suit Over Relacorilant NDA Disclosure 

The latest update is out from Corcept Therapeutics ( ($CORT) ). On March 25, 2026, Corcept Therapeutics announced U.S. FDA approval of Lifyorli (re...

Corcept Wins FDA Approval for Lifyorli Ovarian Cancer Therapy

Shares in biopharma company Corcept Therapeutics ($CORT) climbed as high as 48% to $48.35 following U.S. approval of Lifyorli for treating certain ...

Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?

Analysts have been eager to weigh in on the NA sector with new ratings on Corcept Therapeutics (CORT) and Fiserv (FISV). Corcept Therapeutics (CORT...

Analysts’ Opinions Are Mixed on These NA Stocks: Corcept Therapeutics (CORT) and Fiserv (FISV)

Electrocore (ECOR) has disclosed a new risk, in the Innovation / R&D category. Electrocore faces material risk that its preclinical and clinical pr...

Electrocore’s gammaCore Pipeline Faces Material Trial Disruption Risks From Regulatory, Enrollment and Operational Challenges

Electrocore (($ECOR)) has held its Q4 earnings call. Read on for the main highlights of the call. ElectroCore’s latest earnings call painted a pict...

ElectroCore Earnings Call: Growth Surges, Losses Deepen

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Electrocore (ECOR) and Regeneron (REGN) with bullish...

Analysts Offer Insights on Healthcare Companies: Electrocore (ECOR) and Regeneron (REGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Annexon Biosciences (ANNX) and Electrocore (ECOR) wi...

Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX) and Electrocore (ECOR)

In a report released today, Ben Davis from RBC Capital maintained a Buy rating on Ecora Royalties PLC, with a price target of p175.00. According to...

RBC Capital Sticks to Its Buy Rating for Ecora Royalties PLC (ECOR)

In a report released today, Stephen Baxter from Wells Fargo reiterated a Buy rating on Cencora, with a price target of $429.00. Baxter covers the H...

Wells Fargo Keeps Their Buy Rating on Cencora (COR)

This article spotlights three data center stocks with Strong Buy ratings and massive upsides from analysts.


3 Best Data Center Stocks to Buy, According to Analysts

Corcept Therapeutics ($CORT) told investors relacorilant was a promising next-generation treatment for hypercortisolism supported by clinical data ...

Corcept Therapeutics Lawsuit: CORT Investors Face Losses After FDA Rejection and Alleged Misleading Statements

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Unusual Machines Inc. (UMAC – Research Report), Pr...

Analysts’ Opinions Are Mixed on These Technology Stocks: Unusual Machines Inc. (UMAC), Procore Technologies (PCOR) and Fortinet (FTNT)

Using the TipRanks Stock Screener Tool, we identified three companies that have low Price-to-Earnings (P/E) ratios and hold a “Strong Buy” consensu...

Strong Buy Alert: 3 Low P/E Stocks Poised for Over 40% Gains Ahead

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Procore Technologies (PCOR – Research Report) and Or...

Analysts Offer Insights on Technology Companies: Procore Technologies (PCOR) and Oracle (ORCL)

In a report released today, David Hynes from Canaccord Genuity maintained a Buy rating on Procore Technologies, with a price target of $72.00. Hyne...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	COR	$320.89	0.00%	1.25M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	COR	$320.89	0%	1.25M
3
4
5
6

COR

COR

Get Cencora Inc. Data in Excel

Get Cencora Inc. Data in Excel